NCT03756896Active, not recruitingPhase 2
Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With High-Risk Multiple Myeloma
Maintenance Therapy With Carfilzomib, Pomalidomide and Dexamethasone (CPd) in High-Risk Myeloma Patients: A Phase 2 Study With a Safety Run-In
Source: ClinicalTrials.gov · Last updated 30 Apr 2025
Brief summary (registry, in English)
This phase II trial studies how well carfilzomib, pomalidomide, and dexamethasone work in treating patients with high-risk multiple myeloma. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as pomalidomide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving carfilzomib, pomalidomide, and dexamethasone may work better in treating patients with multiple myeloma.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 29 (actual)
- First submitted
- 27 Nov 2018
- Start date
- 25 Jan 2019
- Primary completion date
- 24 Jun 2025
- Lead sponsor
- Emory University
- Diseases
- Multiple myeloma
- NCT number
- NCT03756896
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 29
- From 25 Jan 2019 to the primary completion date, 24 Jun 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
This page is information, not medical advice. Discuss any trial with your doctor.